|
Originally published In Press as doi:10.1074/jbc.M105008200 on July 30, 2001
J. Biol. Chem., Vol. 276, Issue 40, 37120-37123, October 5, 2001
Are 5-Hydroxytryptamine-preloaded -Cells an Appropriate
Physiologic Model System for Establishing That Insulin Stimulates
Insulin Secretion?*
Walter S.
Zawalich ,
Gregory J.
Tesz, and
Kathleen C.
Zawalich
From the Yale University School of Nursing, New Haven, Connecticut
06536-0740
Received for publication, May 31, 2001, and in revised form, July 24, 2001
 |
ABSTRACT |
The release and oxidation of
5-hydroxytryptamine from 5-hydroxytryptamine-preloaded -cells has
been used as a surrogate marker for insulin secretion. Findings made
using this methodology have been used to support the concept that
insulin stimulates its own release. In the present studies, the effects
of 5-hydroxytryptamine on stimulated insulin secretion from isolated
perifused rat islets was determined. When added together with
stimulatory glucose, 5-hydroxytryptamine (0.5 mM)
significantly reduced both phases of 8 mM glucose-induced
secretion and reduced the first phase of 15 mM
glucose-induced release by 60% without any effect on sustained insulin
release rates. Preloading of -cells with 0.5 mM
5-hydroxytryptamine for 3 h resulted in a more severe impairment of 15 mM glucose-induced secretion. First and second phase
release rates were reduced by 70 and 55%, respectively. In addition,
this pretreatment protocol also abolished 200 µM
tolbutamide-induced insulin secretion from perifused islets. These
findings confirm that 5-hydroxytryptamine is a powerful inhibitor of
stimulated insulin secretion. The responses of
5-hydroxytryptamine-preloaded -cells may not accurately reflect the
biochemical events occurring during the physiologic regulation of
insulin secretion. The suggestion that insulin stimulates its own
secretion based exclusively on amperometric measurements should be reconsidered.
 |
INTRODUCTION |
The concept that insulin exerts biochemical and physiologic
effects on the cell that secretes it, the pancreatic -cell, has been
suggested based on a number of observations. Over 30 years ago (1, 2),
a negative feedback effect of insulin on its own release was proposed.
A large number of subsequent studies (3-9) in which insulin or
connecting peptide levels were measured arrived at a similar
conclusion. We recently reported (10), in agreement with several prior
studies (11, 12), that the phosphatidylinositol 3-kinase
(PI3K)1 inhibitor wortmannin
amplified glucose-induced insulin secretion. This conclusion was based
upon insulin secretion measurements from isolated perifused rat islets
that retain physiologic insulin secretory responses similar to those
observed using the perfused rat pancreas preparation (13-15). We also
suggested that an impairment in PI3K signaling in -cells might be
responsible for the hyperinsulinemia noted in a variety of
insulin-resistant states including obesity and type 2 diabetes. Thus,
whereas disruption of PI3K signaling results in insulin resistance in
peripheral insulin-dependent tissues (16, 17), the same
biochemical alteration in the -cell results in compensatory
hyperinsulinemia. This elegant communications network allows the
-cell to match the degree of insulin resistance and the secretion of
insulin thus maintaining glucose tolerance. This concept presupposes
that insulin exerts a negative feedback effect on its own secretion and
utilizes the same biochemical signaling systems described in liver,
muscle, and adipose tissues (18-20).
In contrast to the numerous studies demonstrating that insulin inhibits
its own secretion (1-9), it has been suggested most recently that
insulin stimulates insulin secretion from the -cell (21).
Amperometrically measured spikes of 5-hydroxytryptamine (5HT) release
from -cells preincubated in 0.5 mM 5HT for 16 h provided the experimental support for this concept. This method takes
advantage of the fact that amperometric measurements of 5HT release
from preloaded -cells can be used as a surrogate marker for insulin
release and has been utilized by several groups (21-26). It is based
upon earlier studies in which 5HT was found to be localized in islet
secretory granules and thought to be cosecreted with insulin (27). Not
all reports, however, agreed with this concept (28). Unfortunately in
none of the electrophysiologic studies (21-26) was glucose-induced
insulin secretion actually assessed to corroborate the amperometric
analyses, and despite previous studies demonstrating an adverse effect
of 5HT on insulin secretion (29, 30), the possibility that 5HT
preloading might negatively affect secretion was not examined in any of
these amperometry studies.
In an attempt to resolve the opposite concepts with regard to the
inhibitory or stimulatory effects of insulin on -cell secretion, we
conducted studies with islets treated with 0.5 mM 5HT. In
agreement with several previous studies (29, 30), we observed that 5HT exerts profound acute and long lasting inhibitory effects on
glucose-induced insulin secretion from perifused rat islets. It also
abolished tolbutamide-induced secretion as well. The concept that
amperometric measurements of 5HT release from -cells reflect the
physiologic regulation of insulin secretion should be reconsidered.
 |
EXPERIMENTAL PROCEDURES |
Islet Isolation--
The detailed methodologies employed to
assess insulin output from collagenase-isolated rat islets have been
described previously (10, 31). Male Harlan Sprague-Dawley rats
(350-475 g) were purchased from Charles River Laboratories, Inc.
(Wilmington, MA). All animals were treated in a manner that complied
with the NIH Guidelines for the Care and Use of Laboratory Animals
(41). The animals were fed ad libitum. After intraperitoneal
Nembutal (pentobarbital sodium, 50 mg/kg; Abbott, North Chicago,
IL)-induced anesthesia, islets were isolated by collagenase digestion
and hand-picked, using a glass loop pipette, under a stereo microscope. They were free of exocrine contamination.
Preloading Studies with 5HT--
After isolation, groups of
16-18 islets were loaded onto nylon filters (Tetko, Inc., Briarcliff
Manor, NY), placed in small glass vials, and incubated for 3 h in
400 µl of a Krebs-Ringer bicarbonate (KRB) solution containing 0.5 mM 5HT plus 5 mM glucose. This solution,
oxygenated and warmed (37 °C), was gently added to the vial with
islets. The vial was capped with a rubber stopper and gassed for
10 s with 95% O2, 5%CO2. The vials were
again gently oxygenated after 90 min. After the preloading period, the
islets still on nylon filters were washed with 5 ml of fresh KRB and perifused as described below.
Perifusion Studies--
Groups of 14-18 freshly isolated or
preincubated islets were perifused with KRB at a flow rate of 1 ml/min
for 30 min, usually with 3 mM glucose, to establish basal
and stable insulin secretory rates. In some experiments 0.5 mM 5HT was included during this period. After this 30-min
stabilization period they were then perifused with the appropriate
agonist or agonist combinations as indicated in the figure legends and
under "Results." Perifusate solutions were gassed with 95%
O2, 5% CO2 and maintained at 37 °C. Insulin
released into the medium was measured by radioimmunoassay (32).
Reagents--
Hanks' solution was used for the islet isolation.
The perifusion medium consisted of 115 mM NaCl, 5 mM KCl, 2.2 mM CaCl2, 1 mM MgCl2, 24 mM NaHCO3,
and 0.17 g/dl bovine serum albumin. The 125I-labeled
insulin used for the insulin assay was purchased from PerkinElmer Life Sciences. Bovine serum albumin
(radioimmunoassay grade), glucose, 5-HT hydrochloride, and the salts
used to make the Hanks' solution and perifusion medium were purchased
from Sigma. Rat insulin standard (lot 615-ZS-157) was the generous gift
of Dr. Gerald Gold, Eli Lilly Co. (Indianapolis, IN). Collagenase (Type
P) was obtained from Roche Molecular Biochemicals.
Statistics--
Statistical significance was determined using
the Student's t test for unpaired data or analysis of
variance in conjunction with the Newman-Keuls test for unpaired data. A
p value less than or equal to 0.05 was taken as significant.
Values presented in the figures and under "Results" represent
means ± S.E. of at least three observations.
 |
RESULTS |
Acute 5HT Exposure Studies--
In the initial series of
experiments islets were perifused immediately after isolation. In
response to 8 mM glucose, insulin secretory rates increased
most significantly during the final 20 min of the perifusion (Fig.
1, top panel). For example,
20, 30, or 40 min after the onset of stimulation with 8 mM
glucose, secretory rates averaged 159 ± 14, 199 ± 25, or
214 ± 18 pg/islet/min (n = 6). The inclusion of
5HT during the stimulatory period with 8 mM glucose
significantly reduced islet insulin secretory responses. For example,
20, 30, or 40 min after the onset of stimulation with 8 mM
glucose, secretory rates now averaged 87 ± 20, 102 ± 15, or
112 ± 12 pg/islet/min (n = 4). Peak first phase
release noted during the initial minutes of 8 mM glucose
stimulation was also impaired by the inclusion of 0.5 mM
5HT. They averaged 89 ± 7 pg/islet/min from control islets and
62 ± 6 pg/islet/min from islets stimulated with the combination
of 8 mM glucose plus 5HT.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 1.
Insulin secretion from perifused rat
islets. Groups of islets were perifused immediately after
isolation. They were perifused with 3 mM glucose
(G3) for 30 min to establish stable, basal rates of release.
Top panel, one group (open circles,
n = 6) was then stimulated for 40 min with 8 mM glucose (G8) alone. The second group
(closed circles, n = 4) was stimulated with
8 mM glucose in the additional presence of 0.5 mM 5HT. Bottom panel, one group (open
circles, n = 8) was then stimulated for 40 min
with 15 mM glucose (G15) alone. The second group
(closed circles, n = 5) was stimulated with
15 mM glucose in the additional presence of 0.5 mM 5HT. Mean values ± S.E. are given in this and
subsequent figures. The asterisk indicates a significant
difference between groups at this time point. This and subsequent
perifusion figures have not been corrected for the dead space in the
perifusion apparatus, 2.5 ml or 2.5 min with a flow rate of 1 ml/min.
|
|
When stimulated with 15 mM glucose, control islets
responded with a brisk biphasic insulin secretory response (Fig. 1,
bottom panel). Peak first phase secretion averaged 177 ± 21 pg/islet/min whereas release rates measured 35-40 min after the
onset of stimulation increased to 834 ± 80 pg/islet/min
(n = 8). The presence of 0.5 mM 5HT during
stimulation with 15 mM glucose significantly reduced peak
first phase secretion, which fell from 177 ± 21 pg/islet/min from
control islets to 76 ± 9 pg/islet/min (n = 4) in
the presence of 5HT, a reduction of ~60%. Rates of insulin secretion
during the final 20 min of stimulation with 15 mM glucose
(745 ± 32 pg/islet/min) were comparable with those from control islets.
Effects of Prior Exposure to 5HT on Stimulated Insulin
Secretion--
In the amperometric studies in which 5HT oxidation was
used as the index of insulin secretion (21-26), cells were pretreated with 0.5 mM 5HT for 4-16 h and stimulated with various
agonists including tolbutamide. In the next series of studies, we
explored the impact of prior exposure to 5HT on insulin secretion. Two different protocols were employed. In the first series of studies, 0.5 mM 5HT was included together with 3 mM glucose
only during the initial 30-min stabilization period of the perifusion
with 3 mM glucose. Similar to the amperometric studies
conducted with 5HT-preloaded islets (21, 24, 25), there was no washout period prior to stimulation (Fig. 2) The
results are given in Fig. 2 and demonstrate that a brief prior exposure
to 0.5 mM 5HT exerted a significant and sustained
inhibitory effect on 15 mM glucose-induced secretion. Most
dramatic was the reduction in peak first phase secretion, which was
decreased to 49 ± 14 pg/islet/min (n = 4). The
impact of 5HT on secretion was evident during the entire 40-min
stimulatory period with 15 mM glucose alone. Thus, despite
its absence from the perifusion medium for 40 min, the adverse effect
of 5HT on release is sustained.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 2.
Prior short term exposure to 5HT impairs 15 mM glucose-induced insulin secretion. Groups of islets
were perifused immediately after isolation. The control group
(open circles) was perifused with 3 mM glucose
alone (G3) for 30 min to establish stable, basal rates of
release. The second group (closed circles) was perifused
with the combination of 3 mM glucose plus 0.5 mM 5-HT for 30 min. Both groups were then stimulated with
15 mM glucose alone for 40 min. The 15 mM
control data (open circles) are the same as those depicted
in Fig. 1. The asterisk indicates a significant difference
between groups at this time point.
|
|
In the next series of experiments, islets were first exposed to 0.5 mM 5HT for 3 h. This period of preexposure was chosen because longer culture periods result in a deterioration of
glucose-induced secretion (33-35), a situation that might complicate
interpretation of the findings. The islets were then perifused for 30 min with 3 mM glucose alone prior to stimulation. The
results are presented in Fig. 3. In
response to 200 µM tolbutamide a small increase in
secretion from control islets was observed only during the initial few
minutes of stimulation (Fig. 3, top panel). This agrees with
previous studies that have demonstrated a marked glucose dependence for
the insulin stimulatory effect of sulfonylurea (36-38). After prior
exposure to 0.5 mM 5HT for 3 h, this minimal secretory
response was abolished.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 3.
Preloading islets with 5HT for 3 h
reduces tolbutamide- and 15 mM glucose-induced
secretion. Groups of islets were isolated, loaded onto nylon
filters, and incubated for 3 h in a KRB solution supplemented with
5 mM glucose. In one group (closed triangles)
0.5 mM 5HT was included during this 3-h period. Islets were
washed with 5 ml of fresh KRB. Top panel, islets
(n = 5 for both groups) were perifused for 30 min with
3 mM glucose and for an additional 30 min with 3 mM glucose plus 200 µM tolbutamide. Only the
first 10 min of the insulin secretory response to the sulfonylurea are
depicted. Bottom panel, islets (n = 9 for
controls and n = 5 for 5HT-pretreated) were perifused
for 30 min with 3 mM glucose and for an additional 40 min
with 15 mM glucose. The asterisk indicates a
significant difference between groups at this time point.
|
|
In response to 15 mM glucose, control islets responded with
a biphasic insulin secretory response (Fig. 3, bottom
panel). First phase release averaged 196 ± 21 pg/islet/min
whereas sustained rates of secretion averaged 570 ± 57 pg/islet/min (n = 9) during the final 5 min of
stimulation. Similar to the findings made when 5HT-preloaded islets
were stimulated with tolbutamide, the response to 15 mM
glucose was significantly reduced by a 3-h exposure to 5HT. Most
dramatic was the reduction in the first phase response, which declined
from 196 ± 21 pg/islet/min to 60 ± 16 pg/islet/min (n = 5). The adverse effect of 5HT preexposure on
glucose-induced insulin release was sustained for at least 70 min.
Release rates measured 35-40 min after the onset of 15 mM
glucose were still significantly less than control islet responses.
They averaged 240 ± 38 pg/islet/min in the 5HT-pretreated islets
at this time point.
 |
DISCUSSION |
In an attempt to improve the time resolution between the
electrical and secretory events that participate in insulin release, several groups have employed amperometry (21-24, 26). This technique has also been applied to insulin receptor substrate-1 gene-disrupted -cells as well (25). Initially employed in studies using adrenal chromaffin cells (39), secretion is detected with this methodology by a
carbon fiber electrode placed next to the cell of interest. As
described by Ashcroft and co-workers (23) "the electrode is held at
or above the oxidation potential of the secreted compound and secretion
monitored by the current associated with the oxidation of the vesicle
contents." The method is only applicable to readily oxidized
compounds, but unfortunately, insulin is not such a compound. To
circumvent this shortcoming of insulin, these groups have preloaded -cells for 4-16 h with 5HT, a highly electroactive compound
(21-24, 26). Because it appears to be confined to secretory granules, it has been assumed in these amperometric studies that the secretion of
5HT accurately reflects the physiologic secretion of insulin. Unfortunately, in none of these aforementioned -cell amperometric studies was insulin secretion actually measured. It was assumed to
occur in parallel with the amperometric changes induced by the
oxidation of 5HT. In the present series of experiments, insulin secretion from perifused rat islets was measured during acute exposure
to or after a 30-min to 3-h preloading period with 5HT. The level of
5HT (0.5 mM) employed was identical to that used in the
amperometric studies. The exposure times to 5HT were not as prolonged.
However, considering the time-dependent inhibitory actions
of 5HT noted in our studies, the adverse effects of more prolonged
exposure to 5HT on stimulated secretion may be even more severe than
demonstrated here.
In response to 8 mM glucose, a modest insulin secretory
response was evoked from control rat islets. Second phase release rates
after 40 min of stimulation were increased 4-6-fold above prestimulatory rates whereas the initial response, although modest, was
approximately doubled. The inclusion of 5HT together with 8 mM glucose significantly reduced both phases of 8 mM glucose-induced secretion. Using a higher glucose level
(15 mM) resulted in a more pronounced first phase response
and a large rising second phase response from control islets. Inclusion
of 5HT during acute stimulation with 15 mM glucose reduced
the peak first phase response by about 60%. Sustained second phase
release rates were comparable with control values.
Preexposure to 0.5 mM 5HT for either 30 min or 3 h
resulted in a profound suppression of both phases of 15 mM
glucose-induced release. Thus, in agreement with previous studies using
mouse islets (29, 30), 5HT is a powerful inhibitor of the insulin secretory response to glucose.
In a recent report (21) and in contrast to other studies in which
insulin or connecting peptide levels were measured (1-7, 9), it was
concluded based on amperometric measurements of 5HT release that
insulin stimulates its own secretion. In addition to insulin, 16-h
5HT-preloaded -cells were also stimulated with 200 µM
tolbutamide in the presence of 3 mM glucose. We performed additional studies utilizing this stimulatory protocol using islets preloaded with 5HT for 3 h. Islets were perifused and stimulated with 200 µM tolbutamide in the presence of 3 mM glucose. Consistent with previous studies using the
perfused rat pancreas (36) or perifused islets (38), a small,
transient, and minimal insulin secretory response that rapidly subsided
was observed. Under conditions employed in these studies and in which
insulin secretion rates were measured, prior exposure to 0.5 mM 5HT for 3 h abolished this weak response to tolbutamide.
What is the experimental basis for suggesting that 5HT secretion
mirrors physiologic insulin release? One of the earliest studies with
5HT (28) demonstrated that neither 20 mM glucose nor the
sulfonylurea glibenclamide mobilized granule-bound 5HT. In fact these
two compounds tended to inhibit the efflux of 5HT under conditions in
which they both stimulated insulin secretion measured in parallel
studies. Other secretion studies demonstrated that 5HT profoundly
reduced stimulated insulin secretion (29, 30). In a subsequent report
(27), a small, transient increase in 5HT release was observed from
perifused mouse islets. One bothersome issue regarding the use of 5HT
as a barometer of insulin secretion is that 11 mM glucose
alone failed to increase 5HT release in most cells studied by Ashcroft
and co-workers (23). Forskolin (10 µM) had to be included
together with glucose. In rat islets at least, 10 mM
glucose is a powerful stimulant of insulin secretion in the absence of
forskolin (40).
According to Aspinwall et al. (24), "Substantial evidence
now exists that demonstrates that 5HT is loaded primarily into secretory vesicles and that 5HT is co-secreted with insulin by exocytosis (22, 23, 26)." The references supporting this claim were
all amperometric studies unsubstantiated by actual insulin secretory
measurements. Our data indicate that 5HT is a powerful inhibitor of the
release process and that results obtained with 5HT have to be
interpreted cautiously.
In conclusion, our studies and several previous reports (29, 30)
demonstrate that prior exposure of -cells to 5HT results in a
profound time-dependent suppression of the insulin
secretory process. The concept that the secretion of 5HT from preloaded -cells reflects physiologic secretion is not supported by these or
other studies (28-30). It is premature to conclude that insulin, under
physiologic conditions, stimulates its own secretion based exclusively
on studies using amperometric measurements of 5HT release without
substantial corroborating data including actual measurements of insulin
secretion from 5HT-preloaded -cells.
 |
FOOTNOTES |
*
These studies were supported by NIDDK, National Institutes
of Health Grant 41230 and by the American Diabetes Association.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Yale University School
of Nursing, P. O. Box 9740, 100 Church St. South, New Haven, CT
06536-0740. Tel.: 203-785-5522; Fax: 203-785-6455; E-mail: walter.zawalich@yale.edu.
Published, JBC Papers in Press, July 30, 2001, DOI 10.1074/jbc.M105008200
 |
ABBREVIATIONS |
The abbreviations used are:
PI3K, phosphatidylinositol 3-kinase;
5HT, 5-hydroxytryptamine;
KRB, Krebs-Ringer bicarbonate.
 |
REFERENCES |
| 1.
|
Sodoyez, J.-C.,
Sodoyez-Goffaux, F.,
and Foà, P. P.
(1969)
Proc. Soc. Exp. Biol.
130,
568-571
|
| 2.
|
Iversen, J.,
and Miles, D. W.
(1971)
Diabetes
20,
1-9
|
| 3.
|
Rappaport, A. M.,
Ohira, S.,
Coddling, J. A.,
Empey, G.,
Kalnins, A.,
Lin, B. J.,
and Haist, R. E.
(1972)
Endocrinology
91,
168-176
|
| 4.
|
Liljenquist, J. E.,
Horwitz, D. L.,
Jennings, A. S.,
Chiasson, J. L.,
Keller, U.,
and Rubenstein, A. H.
(1978)
Diabetes
27,
563-570
|
| 5.
|
Ammon, H. P. T.,
and Verspohl, E.
(1976)
Endocrinology
99,
1469-1476
|
| 6.
|
Loreti, L.,
Dunbar, J. C.,
Chen, S.,
and Foà, P. P.
(1974)
Diabetologia
10,
309-315
|
| 7.
|
Robinson, C.,
Tamborlane, W. V.,
Maggs, D. G.,
Enoksson, S.,
Sherwin, R. S.,
Silver, D.,
Shulman, G. I.,
and Caprio, S.
(1998)
Am. J. Physiol.
274,
E737-E743
|
| 8.
|
Ammon, H. P.,
Reiber, C.,
and Verspohl, E. J.
(1991)
J. Endocrinol.
128,
27-34
|
| 9.
|
Argoud, G. M.,
Schade, D. S.,
and Eaton, R. P.
(1987)
Diabetes
36,
959-962
|
| 10.
|
Zawalich, W. S.,
and Zawalich, K. C.
(2000)
Endocrinology
141,
3287-3295
|
| 11.
|
Hagiwara, S.,
Sakurai, T.,
Tashiro, F.,
Hashimoto, Y.,
Matsuda, Y.,
Nonomura, Y.,
and Miyazaki, J.
(1995)
Biochem. Biophys. Res. Commun.
214,
51-59
|
| 12.
|
Nunoi, K.,
Yasuda, K.,
Tanaka, H.,
Kubota, A.,
Okamoto, Y.,
Adachi, T.,
Shihara, N.,
Uno, M.,
Xu, L. m.,
Kagimoto, S.,
Seino, Y.,
Yamada, Y.,
and Tsuda, K.
(2000)
Biochem. Biophys. Res. Commun.
270,
798-805
|
| 13.
|
Gerich, J. E.,
Charles, M. A.,
and Grodsky, G. M.
(1974)
J. Clin. Invest.
54,
833-841
|
| 14.
|
Curry, D. L.
(1986)
Endocrinology
118,
170-175
|
| 15.
|
Pagliara, A. S.,
Stillings, S. N.,
Hover, B.,
Martin, D. M.,
and Matschinsky, F. M.
(1974)
J. Clin. Invest.
54,
819-932
|
| 16.
|
Kim, Y.-B.,
Nikoulina, S. E.,
Ciaraldi, T. P.,
Henry, R. R.,
and Kahn, B. B.
(1999)
J. Clin. Invest.
104,
733-741
|
| 17.
|
Cusi, K.,
Maezono, K.,
Osman, A.,
Pendergrass, M.,
Patti, M. E.,
Pratipanawatr, T.,
DeFronzo, R. A.,
Kahn, C. R.,
and Mandarino, L. J.
(2000)
J. Clin. Invest.
105,
311-320
|
| 18.
|
Virkamäki, A.,
Ueki, K.,
and Kahn, C. R.
(1999)
J. Clin. Invest.
103,
931-943
|
| 19.
|
Kahn, B. B.,
and Flier, S. J.
(2000)
J. Clin. Invest.
106,
473-480
|
| 20.
|
Dresner, A.,
Laurent, D.,
Marcucci, M.,
Griffin, M. E.,
Dufour, S.,
Cline, G. W.,
Slezak, L. A.,
Anderson, D. K.,
Hundal, R. S.,
Rothman, D. L.,
Petersen, K. F.,
and Shulman, G. I.
(1999)
J. Clin. Invest.
103,
253-259
|
| 21.
|
Aspinwall, C. A.,
Lakey, J. R. T.,
and Kennedy, R. T.
(1999)
J. Biol. Chem.
274,
6360-6365
|
| 22.
|
Smith, P.,
Duchen, M.,
and Ashcroft, F. M.
(1994)
J. Physiol. (Lond.)
475P,
157
|
| 23.
|
Smith, P. A.,
Duchen, M. R.,
and Ashcroft, F. M.
(1995)
Pflügers Arch. Eur. J. Physiol.
430,
808-818
|
| 24.
|
Aspinwall, C. A.,
Brooks, S. A.,
Kennedy, R. T.,
and Lakey, J. R. T.
(1997)
J. Biol. Chem.
272,
31308-31314
|
| 25.
|
Aspinwall, C. A.,
Qian, W.-J.,
Roper, M. G.,
Kulkarni, R. N.,
Kahn, C. R.,
and Kennedy, R. T.
(2000)
J. Biol. Chem.
275,
22331-22338
|
| 26.
|
Zhou, Z.,
and Misler, S.
(1996)
J. Biol. Chem.
270,
270-277
|
| 27.
|
Gylfe, E.
(1978)
J. Endocrinol.
78,
239-248
|
| 28.
|
Hellman, B.,
Lernmark, A.,
Sehlin, J.,
and Täljedal, I.-B.
(1972)
Biochem. Pharmacol.
21,
695-706
|
| 29.
|
Lernmark, A.
(1971)
Horm. Metab. Res.
3,
305-309
|
| 30.
|
Gagliardino, J. J.,
Nierle, C.,
and Pfeiffer, E. F.
(1974)
Diabetologia
10,
411-414
|
| 31.
|
Zawalich, W. S.,
and Zawalich, K. C.
(2000)
J. Endocrinol.
166,
111-120
|
| 32.
|
Albano, J. D. M.,
Ekins, R. P.,
Maritz, G.,
and Turner, R. C.
(1972)
Acta Endocrinol.
70,
487-509
|
| 33.
|
Malaisse-Lagae, F.,
Sener, A.,
and Malaisse, W. J.
(1987)
Acta Diabetol. Lat.
24,
17-25
|
| 34.
|
Metz, S. A.
(1988)
Diabetes
37,
3-7
|
| 35.
|
Zawalich, W. S.,
Zawalich, K. C.,
and Kelley, G. G.
(1995)
Acta Diabetol.
32,
158-164
|
| 36.
|
Grodsky, G. M., G. H., E.,
Fanska, R.,
and Karam, J. H.
(1977)
Fed. Proc.
36,
2714-2719
|
| 37.
|
Curry, D. L.,
Bennett, L. L.,
and Grodsky, G. M.
(1968)
Endocrinology
83,
572-584
|
| 38.
|
Zawalich, W. S.,
and Zawalich, K. C.
(1988)
Diabetes
37,
816-823
|
| 39.
|
Chow, R. H.,
Ruden, L.,
and Neher, E.
(1992)
Nature
356,
60-63
|
| 40.
|
Zawalich, W. S.,
Bonnet-Eymard, M.,
and Zawalich, K. C.
(2000)
Metabolism
49,
1156-1163
|
| 41.
|
National Institutes of Health.
(1985)
NIH Guidelines for the Care and Use of Laboratory Animals, NIH Publication No. 85-23
, National Institutes of Health, Bethesda, MD
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. Eliasson, F. Abdulkader, M. Braun, J. Galvanovskis, M. B. Hoppa, and P. Rorsman
Novel aspects of the molecular mechanisms controlling insulin secretion
J. Physiol.,
July 15, 2008;
586(14):
3313 - 3324.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. E. MacDonald and P. Rorsman
The Ins and Outs of Secretion from Pancreatic {beta}-Cells: Control of Single-Vesicle Exo- and Endocytosis
Physiology,
April 1, 2007;
22(2):
113 - 121.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. I. Hagren and A. Tengholm
Glucose and Insulin Synergistically Activate Phosphatidylinositol 3-Kinase to Trigger Oscillations of Phosphatidylinositol 3,4,5-Trisphosphate in beta-Cells
J. Biol. Chem.,
December 22, 2006;
281(51):
39121 - 39127.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. G. Holz
Epac: A New cAMP-Binding Protein in Support of Glucagon-Like Peptide-1 Receptor-Mediated Signal Transduction in the Pancreatic {beta}-Cell
Diabetes,
January 1, 2004;
53(1):
5 - 13.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Srivastava and H. J. Goren
Insulin Constitutively Secreted by {beta}-Cells Is Necessary for Glucose-Stimulated Insulin Secretion
Diabetes,
August 1, 2003;
52(8):
2049 - 2056.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Kang, J. W. Joseph, O. G. Chepurny, M. Monaco, M. B. Wheeler, J. L. Bos, F. Schwede, H.-G. Genieser, and G. G. Holz
Epac-selective cAMP Analog 8-pCPT-2'-O-Me-cAMP as a Stimulus for Ca2+-induced Ca2+ Release and Exocytosis in Pancreatic beta -Cells
J. Biol. Chem.,
February 28, 2003;
278(10):
8279 - 8285.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Kang and G. G Holz
Amplification of exocytosis by Ca2+-induced Ca2+ release in INS-1 pancreatic {beta} cells
J. Physiol.,
January 1, 2003;
546(1):
175 - 189.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Barker, I. B. Leibiger, B. Leibiger, and P.-O. Berggren
Phosphorylated inositol compounds in beta -cell stimulus-response coupling
Am J Physiol Endocrinol Metab,
December 1, 2002;
283(6):
E1113 - E1122.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Thevenod
Ion channels in secretory granules of the pancreas and their role in exocytosis and release of secretory proteins
Am J Physiol Cell Physiol,
September 1, 2002;
283(3):
C651 - C672.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. S. Zawalich and K. C. Zawalich
Effects of Glucose, Exogenous Insulin, and Carbachol on C-peptide and Insulin Secretion from Isolated Perifused Rat Islets
J. Biol. Chem.,
July 12, 2002;
277(29):
26233 - 26237.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|